Orexin Receptor Agonists

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

A same-day patent settlement with Jazz clears the path for Lumryz as Alkermes targets a faster push into sleep medicine.